Transcriptome analysis of the hippocampus in novel rat model of febrile seizures

PLoS One. 2014 Apr 15;9(4):e95237. doi: 10.1371/journal.pone.0095237. eCollection 2014.

Abstract

Febrile seizures (FS) are the most common type of convulsive events in infants and young children, but the precise underlying genetic mechanism remains to be explored. To investigate the underlying pathogenic factors in FS and subsequent epilepsy, alterations in gene expression between the two new strains of rats (hyperthermia-prone [HP] vs hyperthermia-resistant [HR]), were investigated by using the Whole Rat Genome Oligo Microarray. This process identified 1,140 differentially expressed genes (DEGs; 602 upregulated and 538 downregulated), which were analyzed to determine significant Gene Ontology (GO) categories, signaling pathways and gene networks. Based on the GO analyses, the modified genes are closely related to various FS pathogenesis factors, including immune and inflammatory responses and ion transport. Certain DEGs identified have not been previously examined in relation to FS pathogenesis. Among these genes is dipeptidyl peptidase 4 (DPP4), a gene closely linked to interleukin 6 (IL-6), which played a key role in the gene network analysis. Furthermore, sitagliptin, a DPP4 inhibitor significantly decreased epileptic discharge in rats, observed via electroencephalogram, suggesting an important role for DPP4 in FS. The effectiveness of sitagliptin in reducing seizure activity may occur through a mechanism that stabilizes cellular Ca2+ homeostasis. In addition, DPP4 expression may be regulated by DNA methylation. The hippocampal gene expression profiles in novel rat models of FS provides a large database of candidate genes and pathways, which will be useful for researchers interested in disorders of neuronal excitability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Dipeptidyl-Peptidase IV Inhibitors / pharmacology
  • Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
  • Disease Models, Animal
  • Gene Expression Profiling*
  • Gene Ontology
  • Gene Regulatory Networks / drug effects
  • Hippocampus / drug effects
  • Hippocampus / metabolism*
  • Pyrazines / pharmacology
  • Pyrazines / therapeutic use
  • Rats
  • Rats, Sprague-Dawley
  • Seizures, Febrile / drug therapy
  • Seizures, Febrile / genetics*
  • Sitagliptin Phosphate
  • Triazoles / pharmacology
  • Triazoles / therapeutic use

Substances

  • Dipeptidyl-Peptidase IV Inhibitors
  • Pyrazines
  • Triazoles
  • Sitagliptin Phosphate

Grants and funding

This work was supported by the National Natural Sciences Foundation of China (81371422, 81171127, and 81100970), the National Basic Research Program of China (2010CB529803), the National Science and Technology Major Projects of New Drugs (2012ZX09103301-028), Translational Medical Research Fund of Wuhan University school of medicine, and National Natural Sciences Foundation of China No. 81171577. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.